Equine gastric treatment is getting more lesion-specific

Equine gastric disease remains common in practice, but the treatment conversation is getting more nuanced. A recent sponsored explainer in The Horse reiterates that successful care begins with accurate diagnosis and then combines pharmacologic therapy with management changes, a message that aligns with the broader literature on equine squamous gastric disease and equine glandular gastric disease. The key shift is not a brand-new drug, but a clearer emphasis that lesion location matters, recurrence is common, and some long-used adjuncts still have thinner evidence than many pet parents assume. (thehorse.com)

That distinction has been building for years. Reviews of equine gastric ulcer syndrome now consistently separate squamous disease, which is largely acid-exposure driven, from glandular disease, which appears more tied to impaired mucosal defense and inflammation. That matters because horses with squamous lesions often respond well to acid suppression, while glandular cases can be slower to heal and more frustrating in the field. Management remains central in both settings, especially forage access, reduced fasting, and changes to training or stress exposure to reduce recurrence after treatment stops. (pubmed.ncbi.nlm.nih.gov)

On the pharmacology side, omeprazole remains the anchor therapy. In the U.S., GastroGard is FDA-approved for treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older. Prescribing information describes treatment at 4 mg/kg once daily for 28 days, with a lower-dose follow-on phase to reduce recurrence, and pivotal data showed ulcers healed or improved in 92% of treated horses, while recurrence prevention was achieved in 84% during continued lower-dose administration. Those data, however, are best understood as strongest for squamous disease and for the broader regulatory category of gastric ulcers, not as a guarantee of equal performance in every glandular case seen in referral or sports medicine practice. (animalhealth.boehringer-ingelheim.com)

That’s where the newer and older adjunct literature becomes relevant. A University of Illinois summary of experimental work reported lower glandular lesion scores with omeprazole than sucralfate in a feed-fast/NSAID model, supporting omeprazole as a reasonable first-line gastroprotectant in that setting. At the same time, other reviews note that H2-receptor antagonists are generally less effective than omeprazole in adult horses, and some are not licensed for equine use. For difficult glandular cases, a 2019 study indexed in PubMed found misoprostol was superior to combined omeprazole-sucralfate for treatment of equine glandular gastric disease, reinforcing the idea that persistent EGGD may need a different playbook than routine ESGD. (vetmed.illinois.edu)

Interest in non-drug adjuncts is also clearly not going away. The new Equine Veterinary Journal trial highlighted in your source set tested a nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment in 30 horses. The blinded, randomized, placebo-controlled study found no significant prevention of ulcer recurrence by gastroscopy, even though salivary biomarkers shifted in ways that may suggest improved mucosal health. That’s a useful signal for clinicians: biomarker movement may be biologically interesting, but it doesn’t yet substitute for endoscopic outcomes when discussing recurrence prevention with clients. (pubmed.ncbi.nlm.nih.gov)

Industry and educational commentary broadly lands in the same place. Extension and equine education sources continue to describe omeprazole as the standard pharmacologic option, while emphasizing that constant forage access and other management interventions are essential to reduce relapse risk. Several reviews also caution that recurrence after discontinuation remains a real problem, particularly if the horse returns to the same training, feeding, transport, or confinement conditions that contributed to disease in the first place. (extension.usu.edu)

Why it matters: For veterinary professionals, this is less a story about a new product launch than about clinical precision. Horses with suspected gastric disease still need a diagnosis-driven plan, ideally with gastroscopy, because the prognosis, expected response time, and best adjuncts differ between ESGD and EGGD. The evidence still supports omeprazole as first-line therapy, but it also supports setting expectations early: glandular disease may require longer follow-up, alternative adjuncts such as misoprostol in selected cases, and a stronger focus on management than some pet parents expect when they hear “ulcer medication.” (thehorse.com)

What to watch: The next phase of this conversation will likely center on recurrence prevention after omeprazole, better evidence for adjunctive therapies in EGGD, and whether future nutraceutical studies can translate biomarker changes into consistent endoscopic and clinical benefit. (pubmed.ncbi.nlm.nih.gov)